<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> represents the cornerstone of treatment for type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Traditionally, <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF) was considered a contraindication to its use </plain></SENT>
<SENT sid="2" pm="."><plain>However, more recent evidence has shown that this should no longer be the case </plain></SENT>
<SENT sid="3" pm="."><plain>Indeed, studies have demonstrated that <z:chebi fb="0" ids="6801">metformin</z:chebi> may even reduce the risk of incident HF and mortality in diabetic patients, while improving up to 2-year survival rates in those with HF </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, it appears to exert cardioprotective actions </plain></SENT>
<SENT sid="5" pm="."><plain>Although longer follow-up data and more explicit information about the situation in patients with very advanced HF are needed, the cardiac safety of <z:chebi fb="0" ids="6801">metformin</z:chebi> has profound clinical implications and may be anticipated to further encourage its widespread use </plain></SENT>
</text></document>